(Q26471052)

1 July 2019

meta-analysis

0 references

review article

1 reference

title

Cannabinoids for fibromyalgia (English)

1 reference

1 July 2019

0 references

0 references

5

Winfried Häuser

0 references

Mary-Ann Fitzcharles

3

object named as

Mary-Ann Fitzcharles

0 references

Brian Walitt

1

object named as

Brian Walitt

0 references

Petra Klose

object named as

Petra Klose

2

0 references

author name string

Tudor Phillips

4

1 reference

1 July 2019

publication date

18 July 2016

1 reference

1 July 2019

Cochrane Database of Systematic Reviews

published in

1 reference

1 July 2019

volume

7

1 reference

1 July 2019

page(s)

CD011694

1 reference

1 July 2019

Nabilone for the treatment of pain in fibromyalgia

cites work

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

The effects of nabilone on sleep in fibromyalgia: results of a randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

The fibromyalgia family study: a genome-wide linkage scan study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

GRADE guidelines: 3. Rating the quality of evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Minimal clinically important difference in the fibromyalgia impact questionnaire

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Pathophysiology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

The association between incident self-reported fibromyalgia and nonpsychiatric factors: 25-years follow-up of the Adventist Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Fibromyalgia: a clinical review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Dronabinol and chronic pain: importance of mechanistic considerations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Interpreting the clinical importance of treatment outcomes in chronic pain clinical trials: IMMPACT recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Fibromyalgia syndrome. General principles and coordination of clinical care and patient education

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

2012 Canadian Guidelines for the diagnosis and management of fibromyalgia syndrome: executive summary

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

The dilemma of medical marijuana use by rheumatology patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Cannabis use in patients with fibromyalgia: effect on symptoms relief and health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

The endocannabinoid system and pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Contributions of endocannabinoid signaling to psychiatric disorders in humans: genetic and biochemical evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Emotional, physical, and sexual abuse in fibromyalgia syndrome: a systematic review with meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Posttraumatic stress disorder in fibromyalgia syndrome: prevalence, temporal relationship between posttraumatic stress and fibromyalgia symptoms, and impact on clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Serotonin and noradrenaline reuptake inhibitors (SNRIs) for fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Fibromyalgia syndrome: a somatoform disorder?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Review of pharmacological therapies in fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Assessing the quality of reports of randomized clinical trials: is blinding necessary?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Medicinal use of cannabis: history and current status

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Drugs for neuropathic pain.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Meta-analysis in clinical research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Candidate gene studies of fibromyalgia: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Amygdala activity contributes to the dissociative effect of cannabis on pain perception

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Dual blockade of FAAH and MAGL identifies behavioral processes regulated by endocannabinoid crosstalk in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Cannabinoids for treatment of chronic non-cancer pain; a systematic review of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Size is everything--large amounts of information are needed to overcome random effects in estimating direction and magnitude of treatment effects

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Pregabalin for acute and chronic pain in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

"Evidence" in chronic pain--establishing best practice in the reporting of systematic reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Fibromyalgia: Moderate and substantial pain intensity reduction predicts improvement in other outcomes and substantial quality of life gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Numbers-needed-to-treat analyses--do timing, dropouts, and outcome matter? Pooled analysis of two randomized, placebo-controlled chronic low back pain trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Responder analysis for pain relief and numbers needed to treat in a meta-analysis of etoricoxib osteoarthritis trials: bridging a gap between clinical trials and clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Gabapentin for chronic neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Minimum efficacy criteria for comparisons between treatments using individual patient meta-analysis of acute pain trials: examples of etoricoxib, paracetamol, ibuprofen, and ibuprofen/paracetamol combinations after third molar extraction

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Mean analgesic consumption is inappropriate for testing analgesic efficacy in post-operative pain: analysis and alternative suggestion

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Amitriptyline for neuropathic pain and fibromyalgia in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Estimate at your peril: imputation methods for patient withdrawal can bias efficacy outcomes in chronic pain trials using responder analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Pain measures and cut-offs - 'no worse than mild pain' as a simple, universal outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Expect analgesic failure; pursue analgesic success

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Duloxetine use in chronic painful conditions--individual patient data responder analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

The costs and consequences of adequately managed chronic non-cancer pain and chronic neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Association between physical exercise, body mass index, and risk of fibromyalgia: longitudinal data from the Norwegian Nord-Trøndelag Health Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Sleep problems and risk of fibromyalgia: longitudinal data on an adult female population in Norway

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Relation of distribution- and anchor-based approaches in interpretation of changes in health-related quality of life

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Objective evidence that small-fiber polyneuropathy underlies some illnesses currently labeled as fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Drug development: The treasure chest.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

The endocannabinoid system as an emerging target of pharmacotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Worldwide epidemiology of fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

[Opioids in chronic osteoarthritis pain. A systematic review and meta-analysis of efficacy, tolerability and safety in randomized placebo-controlled studies of at least 4 weeks duration].

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Delta-9-THC based monotherapy in fibromyalgia patients on experimentally induced pain, axon reflex flare, and pain relief

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Etiology and pathophysiology of fibromyalgia syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Association of herbal cannabis use with negative psychosocial parameters in patients with fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Pregabalin in fibromyalgia--responder analysis from individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Duloxetine for painful diabetic neuropathy and fibromyalgia pain: systematic review of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Fibromyalgia: a stress disorder? Piecing the biopsychosocial puzzle together

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Tetrahydrocannabinol (Delta 9-THC) Treatment in Chronic Central Neuropathic Pain and Fibromyalgia Patients: Results of a Multicenter Survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Antiepileptic drugs for neuropathic pain and fibromyalgia - an overview of Cochrane reviews

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

The American College of Rheumatology 1990 Criteria for the Classification of Fibromyalgia. Report of the Multicenter Criteria Committee

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

The American College of Rheumatology preliminary diagnostic criteria for fibromyalgia and measurement of symptom severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Fibromyalgia criteria and severity scales for clinical and epidemiological studies: a modification of the ACR Preliminary Diagnostic Criteria for Fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Fibromyalgia prevalence, somatic symptom reporting, and the dimensionality of polysymptomatic distress: results from a survey of the general population.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

What is fibromyalgia, how is it diagnosed, and what does it really mean?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Central sensitivity syndromes: a new paradigm and group nosology for fibromyalgia and overlapping conditions, and the related issue of disease versus illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Systematic review with meta-analysis: cytokines in fibromyalgia syndrome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Anticonvulsants for fibromyalgia

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

Prognostic factors for the development of fibromyalgia in women with self-reported musculoskeletal pain. A prospective study

21 January 2018

1 reference

12 December 2020

Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions?

1 reference

12 December 2020

Patient-centered perspective on treatment outcomes in chronic pain

1 reference

12 December 2020

[Influence of depression on fibromyalgia : A systematic review]

1 reference

12 December 2020

Small fibre pathology in patients with fibromyalgia syndrome

1 reference

12 December 2020

Adverse health effects of marijuana use

1 reference

12 December 2020

Risks associated with the non-medicinal use of cannabis

1 reference

12 December 2020

Reply: Small fibre neuropathy, fibromyalgia and dorsal root ganglia sodium channels

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011694.PUB2

7 January 2021

inferred from DOI database lookup

Identifiers

DOI

10.1002/14651858.CD011694.PUB2

1 reference

1 July 2019

PMCID

6457965

1 reference

1 July 2019

PubMed ID

27428009

1 reference

1 July 2019